Celularity (CELU) Current Deferred Revenue (2019 - 2025)

Celularity (CELU) has reported Current Deferred Revenue for 7 consecutive years, with $8.1 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Deferred Revenue rose 28.76% year-over-year to $8.1 million in Q4 2025; TTM through Dec 2025 was $8.1 million, a 28.76% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 28.76% from the prior year.
• Current Deferred Revenue was $8.1 million for Q4 2025 at Celularity, down from $8.3 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $11.9 million in Q1 2021 and troughed at $3.8 million in Q3 2021.
• A 5-year average of $6.1 million and a median of $6.0 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue tumbled 72.08% in 2021 and jumped 34.2% in 2024, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $4.1 million in 2021, then increased by 10.45% to $4.5 million in 2022, then soared by 34.02% to $6.0 million in 2023, then advanced by 3.9% to $6.3 million in 2024, then rose by 28.76% to $8.1 million in 2025.
• The last three Current Deferred Revenue figures came in at $8.1 million (Q4 2025), $8.3 million (Q3 2025), and $6.4 million (Q2 2025), per Business Quant data.